Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile

ABSTRACT

Background: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported. Objective: To evaluate the effectiveness of natalizumab treatment in PwRMS in Argentina and Chile, in clinical practice. Methods: We conducted a multicenter retrospective and observational study. We reviewed the medical records of PwRMS who had been treated with natalizumab for at least one year, without any interruption in MS treatment that lasted more than 12 weeks. We analyzed changes in annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score and magnetic resonance imaging (MRI). Results: We enrolled 117 PwRMS treated with natalizumab. Natalizumab treatment was associated with a significant reduction in ARR from baseline after one year and two years of treatment (from 1.97 to 0.06 and 0.09 respectively; p<0.01 at each time point). From baseline, EDSS scores were reduced by 0.71 and 0.73 points at one and two years, respectively (p<0.01). No worsening of disability was observed in 82.9 and 67.5% of PwRMS at one and two years, respectively. The improvement in disability was 44.4% at one year and 39.3% at two years. During natalizumab treatment, the number of relapse-related hospitalizations was significantly reduced (p<0.01). MRI lesions (new/enlarging T2 or gadolinium-enhancing) were significantly reduced, compared with baseline. No evidence of disease activity was observed in 65% at two years of natalizumab treatment. Conclusions: Natalizumab significantly reduced disease activity in PwRMS in Argentina and Chile, in clinical practice. Natalizumab also decreased the number of hospitalizations compared with pre-natalizumab treatment.

RESUMEN

Antecedentes: La efectividad de Natalizumab en personas con esclerosis múltiple recurrente (PwRMS) en Argentina y Chile no se ha reportado. Objetivo: Evaluar la efectividad del tratamiento con Natalizumab en PwRMS en Argentina y Chile en la práctica clínica. Métodos: Estudio multicéntrico, retrospectivo y observacional. Revisamos los registros médicos de PwRMS que fueron tratados con Natalizumab al menos 1 año, sin interrupción de tratamiento para EM durante más de 12 semanas. Analizamos los cambios en la tasa anualizada de recaídas (ARR), escala de discapacidad expandida (EDSS) y resonancia magnética (MRI). Resultados: Se incluyeron 117 PwRMS. El tratamiento con Natalizumab se asoció con una reducción significativa de la tasa anualizada de recaídas (ARR) cada 1 y 2 años (de 1.97 a 0.06 y 0.09, respectivamente; p<0.01 en ambos casos). El EDSS se redujo 0,71 y 0,73 puntos al año 1 y 2, respectivamente (p<0,01). No se observó empeoramiento del EDSS en 82,9 y 67,5% de los PwRMS al año 1 y 2, respectivamente. La mejoría del EDSS fue 44,4 y 39,3% al año 1 y 2, respectivamente. El número de hospitalizaciones se redujo significativamente (p<0,01). Las lesiones en MRI (nuevas/agrandadas en T2 o con realce con gadolinio) se redujeron significativamente en comparación con el valor basal. No se observó evidencia de actividad de la enfermedad en el 65% de los PwRMS a 2 los años. Conclusiones: Natalizumab redujo significativamente la actividad de la enfermedad en PwRMS de Argentina y Chile en la práctica clínica. Además, disminuyó el número de hospitalizaciones comparado con el tratamiento previo.

Keywords:

Observational Study - Effectiveness - Multiple Sclerosis - Natalizumab - Latin America

Palabras clave:

Estudio Observacional - Efectividad - Esclerosis Múltiple - Natalizumab - América

Authors’ contributions:

VDA: contributed substantially to the conception and design of the study. All authors contributed equally to the collection, analysis, and interpretation of data; to the writing and critical review of the manuscript; and to the approval of the final version to be published.

Support:

This study was supported by Biogen S.R.L. Argentina. Biogen reviewed the manuscript and provided feedback on the manuscript. However, the authors had full editorial control over the manuscript and provided their final approval for all content.

Publication History

Received: 02 July 2020

Accepted: 01 September 2020

Article published online:
07 June 2023

• References

• 1 Polman, CH, Reingold, SC., Banwell, B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. https://doi.org/10.1002/ana.22366
• 2 Cristiano E, Patrucco L, Rojas JI. A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol. 2008 Dec;15(12):1273-8. https://doi.org/10.1111/j.1468-1331.2008.02330.x
• 3 Cristiano E, Patrucco L, Miguez J, Giunta D, Correale J, Fiol M, et al. Increasing prevalence of multiple sclerosis in Buenos Aires, Argentina. Mult Scler Relat Disord. 2016 Sep;9:91-4. https://doi.org/10.1016/j.msard.2016.07.007
• 4 Tysabri label in Argentina [accessed on Apr 10, 2017]. Available at: http://www.anmat.gov.ar/boletin_anmat/Abril_2017/Dispo_3395-17.pdf
• 5 Tysabri label in Chile [accessed on Oct 15, 2014]. Available at: http://www.ispch.cl/sites/default/files/tysabri_300mg_15ml.pdf
• 6 Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, et al. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019 Jun;19(1):116. https://doi.org/10.1186/s12883-019-1337-z
• 7 van Pesch V, Sindic CJ, Fernández O. Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies. Clin Neurol Neurosurg. 2016 Oct;149:55-63. https://doi.org/10.1016/j.clineuro.2016.07.001
• 8 Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1190-7. https://doi.org/10.1136/jnnp-2013-306936
• 9 Kurtzke JF. Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. https://doi.org/10.1212/wnl.33.11.1444
• 10 Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar;8(3):254-60. https://doi.org/10.1016/S1474-4422(09)70021-3
• 11 Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009 Mar;256(3):405-15. https://doi.org/10.1007/s00415-009-0093-1
• 12 Alonso R, Contentti EC, Imhoff G, Lopez PA, Rubstein A, Tizio S. Barriers against a successful MS treatment: The importance of effectiveness beyond efficacy. Mult Scler Relat Disord. 2019 May;30:129-135. https://doi.org/10.1016/j.msard.2019.01.056
• 13 Kappos, L., Butzkueven, H., Spelman, T., Trojano, M., Wiendl, H., Jiang, X., et al. Real-world data from over 10 years in the TYSABRI® Observational Program: Long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients. Rev Neurol. 2019 Apr;175(Suppl 1):S101-S102. https://doi.org/10.1016/j.neurol.2019.01.271
• 14 Krysko KM, O’Connor PW. The Toronto observational study of natalizumab in multiple sclerosis. Can J Neurol Sci. 2011 May;38(3):422-8. https://doi.org/10.1017/s0317167100011811
• 15 Correia I, Batista S, Galego O, Marques IB, Jesus-Ribeiro J, Martins AI, et al. Long-term effectiveness and safety of natalizumab in a Portuguese population. Int Immunopharmacol. 2017 May;46:105-11. https://doi.org/10.1016/j.intimp.2017.03.006
• 16 Outteryck O, Ongagna JC, Zéphir H, Fleury MC, Lacour A, Blanc F, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010 Feb;257(2):207-11. https://doi.org/10.1007/s00415-009-5294-0
• 17 Melin A, Outteryck O, Collongues N, Zéphir H, Fleury MC, Blanc F, et al. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol. 2012 Jun;259(6):1215-21. https://doi.org/10.1007/s00415-011-6339-8
• 18 Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, et al. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol. 2014;21(1):40-8. https://doi.org/10.1111/ene.12204
• 19 Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol. 2012 May;259(5):898-905. https://doi.org/10.1007/s00415-011-6275-7
• 20 Kallweit U, Jelcic I, Braun N, Fischer H, Zörner B, Schreiner B, et al. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol. 2012 Mar-Apr;35(2):77-80. https://doi.org/10.1097/WNF.0b013e31824644e6
• 21 Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol. 2010;63(2):101-6. https://doi.org/10.1159/000276400
• 22 Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011 Jun;17(6):708-19. https://doi.org/10.1177/1352458510394701
• 23 Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009 Mar;16(3):420-3. https://doi.org/10.1111/j.1468-1331.2008.02517.x
• 24 Belachew S, Phan-Ba R, Bartholomé E, Delvaux V, Hansen I, Calay P, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2011 Feb;18(2):240-5. https://doi.org/10.1111/j.1468-1331.2010.03112.x
• 25 Mancardi GL, Tedeschi G, Amato MP, D’Alessandro R, Drago F, Milanese C, et al. Three years of experience: the Italian registry and safety data update Neurol Sci. 2011 Jan;31 Suppl 3:295-7. https://doi.org/10.1007/s10072-010-0356-8
• 26 Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, et al. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):147-54. https://doi.org/10.1177/039463201402700201
• 27 Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. 2011 Jan;31 Suppl 3:299-302. https://doi.org/10.1007/s10072-010-0344-z
• 28 Prosperini L, Giannì C, Fubelli F, Marinelli F, Pozzilli C. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. J Neurol Sci. 2012 Dec;323(1-2):104-12. https://doi.org/10.1016/j.jns.2012.08.027
• 29 Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, et al. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci. 2012 Dec;323(1-2):104-12. https://doi.org/10.1016/j.jns.2012.08.027
• 30 Fernández O, Oreja-Guevara C, Arroyo R, Izquierdo G, Pérez JL, Montalban X. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol. 2012 Sep;259(9):1814-23. https://doi.org/10.1007/s00415-012-6414-9
• 31 Fernández-Megía MJ, Casanova B, Magraner MJ, Font-Noguera I, Poveda-Andrés JL. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis. Farm Hosp. 2011 Mar-Apr;35(2):75-9. https://doi.org/10.1016/j.farma.2010.02.003
• 32 van Pesch V, Bartholomé E, Bissay V, Bouquiaux O, Bureau M, Caekebeke J, et al. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. Acta Neurol Belg. 2014 Sep;114(3):167-78. https://doi.org/10.1007/s13760-014-0308-9
• 33 Trojano M, Spelman T, Butzkueven H, Kappos L, Wiendl H, Chang I, et al. Natalizumab is associated with a reduction in relapse-related hospitalisations and steroid treatment in relapsing-remitting multiple sclerosis patients enrolled in the TYSABRI® Observational Program. ECTRIMS Online Library. Trojano M. 10/10/18; 228441; P597.
• 34 Alroughani R, Al Hashel J, Thussu A, Ahmed SF. Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait. Med Princ Pract. 2013;22(5):495-9. https://doi.org/10.1159/000351568
• 35 Fernández O, Alvarenga MP, Guerrero M, León A, Alonso A, López-Madrona JC, et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler. 2011 Feb;17(2):192-7. https://doi.org/10.1177/1352458510385507
• 36 Phillips JT, Giovannoni G, Lublin FD, O’Connor PW, Polman CH, Willoughby E, et al. Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011 Aug;17(8):970-9. https://doi.org/10.1177/1352458511399611